– USA, CA – Vivani Medical, Inc. (Nasdaq: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of Dan Bradbury to its Board of Directors.
“Dan has served as an advisor to Vivani and our legacy company, Nano Precision Medical, since 2017, and his guidance has been invaluable. As a member of Vivani’s distinguished board of directors, Dan’s leadership expertise and deep insight and experience developing and commercializing the world’s first GLP-1 drug (exenatide injection) will continue to prove pivotal as we focus our efforts on delivering miniature, long-term GLP-1 implants for the treatment of obesity, type 2 diabetes, and potentially, other serious chronic diseases,” said CEO Adam Mendelsohn.
Dan Bradbury will also join the Audit Committee.
About Daniel Bradbury
Dan Bradbury is the former President, CEO, and Director of Amylin Pharmaceuticals, a biopharmaceutical company focused on the development of drug candidates for the treatment of serious metabolic diseases. He served as Amylin’s CEO from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7.1B in August 2012. Before joining Amylin in 1994, he worked in marketing and sales roles for 10 years at SmithKline Beecham Pharmaceuticals.
Dan Bradbury serves on the board of directors of Castle Biosciences, Inc. and Equillium, Inc., and several private companies and philanthropic organizations. Bradbury previously served on the board of directors of Biocon Limited, Corcept Therapeutics Inc., Geron Inc., Illumina Inc., and Intercept Pharmaceuticals Inc.
Dan Bradbury earned a Bachelor of Pharmacy degree from Nottingham University and a Diploma in Management Studies from the University of West London in the United Kingdom.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal platform, Vivani Medical develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods to guarantee adherence and potentially improve medication tolerability. Vivani’s lead programs NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively. Both NPM-115 and NPM-119 are exenatide-based products with a higher dose associated with NPM-115 for the treatment of chronic weight management in obese or overweight patients. These NanoPortalTM implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease medications face significant challenges in achieving positive real-world effectiveness.
Vivani’s wholly-owned subsidiary Cortigent is developing targeted neurostimulation systems intended to help patients recover critical body functions. Investigational devices include Orion, designed to provide artificial vision to people who are profoundly blind, and a new system intended to accelerate the recovery of arm and hand function in patients who are partially paralyzed due to stroke. Vivani continues to assess strategic options for advancing Cortigent’s pioneering technology.
SOURCE: https://vivani.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.